Gujarat Themis Biosyn

Vapi, India Founded: 1981 • Age: 45 yrs Listed
Application development services are provided from Vapi, India.

About Gujarat Themis Biosyn

Gujarat Themis Biosyn is a publicly listed company based in Vapi (India) founded in 1981. Application development services are provided from Vapi, India. The company has 224 employees. Gujarat Themis Biosyn has completed 1 acquisition, including MicroBiopharm Japan. Its chief executive, as recorded, is Tapas Bhudebendranath Guhathakurata. Its Indian entity Gujarat Themis Biosyn Ltd reported revenue of β‚Ή168 Cr. Gujarat Themis Biosyn offers products and services including Rifampicin. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Similar companies include Laurus Labs, Symbiotec and Jubilant Pharma; 2 of its 3 listed similar companies have raised funding.

Company details

Gujarat Themis Biosyn was established in 1981 and is headquartered in Vapi, India. Operations are centered on the information technology sector, where application development services are delivered to support software needs. The company functions within the software services industry, focusing on custom application solutions. Leadership is provided by CEO Tapas Bhudebendranath Guhathakurata, with activities conducted primarily in the Indian market.

  • Headquarters Vapi, India
  • Employees 224
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website gtbl.in
  • Social LinkedIn
  • Legal Name Gujarat Themis Biosyn Ltd
Key Metrics
  • Market Cap
    ₹4,676 Cr

    GUJTHEM · NSE

  • Share Price
    ₹349.00

    -2.85% today

  • Revenue
    ₹166 Cr

    FY 2025-26 · +10.0% YoY

  • EBITDA
    ₹76.41 Cr

    Margin 46.1%

  • Net Profit
    ₹46.67 Cr

    FY 2025-26 · -4.3% YoY

  • P/E (TTM)
    108.4x

    P/B 6.7x

  • ROE
    17.4%

    ROCE 18.1%

  • Debt / Equity
    0.36

    Interest cover 6.0x

  • Employee Count
    224
  • Investments & Acquisitions

Products & Services of Gujarat Themis Biosyn

Gujarat Themis Biosyn offers a comprehensive portfolio of products and services, including Rifampicin.

Rifampicin
Anti-tuberculosis Drug

Antibiotic for tuberculosis treatment manufactured commercially.

Board of directors of Gujarat Themis Biosyn Ltd (Gujarat Themis Biosyn)

Gujarat Themis Biosyn Ltd is the primary company behind Gujarat Themis Biosyn. The board of Gujarat Themis Biosyn Ltd currently have 7 directors; the longest-serving is Dinesh Shantilal Patel, appointed in 1992. 28 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Dinesh Shantilal Patel
DIN 00033273
Director25 May 199234 yrs 5 moGujarat Themis Biosyn Ltd
Sachin Dinesh Patel
DIN 00033353
Managing Director25 Oct 200818 yrsGujarat Themis Biosyn Ltd
Kirandeep Kaur Madan
DIN 00686547
Director01 May 20215 yrs 6 moGujarat Themis Biosyn Ltd
Hitesh Dharmasinh Gajaria
DIN 10044310
Director14 May 20242 yrs 6 moGujarat Themis Biosyn Ltd
Kumarapuram Gopalakrishnan Ananthakrishnan
DIN 00019325
Director26 Jul 20242 yrs 3 moGujarat Themis Biosyn Ltd
Nihar Ajay Parikh
DIN 02475787
Director01 Aug 20251 yr 3 moGujarat Themis Biosyn Ltd
Rajneesh Kedarnath Anand
DIN 00134856
Additional Director10 Nov 20251 yrGujarat Themis Biosyn Ltd

People of Gujarat Themis Biosyn

1 people are tracked at Gujarat Themis Biosyn (1 in leadership); the tracked headcount is 224.

NameRoleGroup
Tapas Bhudebendranath Guhathakurata
CEOLeadership
Premium access

Complete people profiles for Gujarat Themis Biosyn

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Gujarat Themis Biosyn

Gujarat Themis Biosyn is a publicly listed company on the NSE with ticker symbol GUJTHEM in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date25 Feb 2025
  • Listed onNSE: GUJTHEM
  • Listed entityGujarat Themis Biosyn Ltd
  • Exchange sectorHealth technology
  • ISININE942C01045
  • Share price₹389.15 (+4.33% on the day) · 2026-10-14
  • Market capitalisation₹4,836 Cr
  • Price to earnings87.1
  • EPS (diluted, trailing year)₹4.47
  • Dividend yield0.18%
  • Volume (last session)474,150

Financials of Gujarat Themis Biosyn

Exchange-reported figures of Gujarat Themis Biosyn Ltd, the listed company behind Gujarat Themis Biosyn (NSE: GUJTHEM).

Financial Highlights

FY 2025-26 Β· Standalone
Revenue
₹166 Cr
+10.0% YoY
EBITDA
₹76.41 Cr
+11.0% YoY
Profit After Tax
₹46.67 Cr
-4.3% YoY
Net Worth
₹288 Cr
+15.9% YoY
Total Assets
₹451 Cr
+61.2% YoY
Total Debt
₹162 Cr
+431.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue16615117014811590.5685.12
Revenue growth+10.0%-11.2%+14.4%+29.2%+26.8%+6.4%-
EBITDA76.4168.8478.7273.6458.0540.3331.84
EBITDA margin+46.1%+45.7%+46.4%+49.6%+50.5%+44.5%+37.4%
Profit before tax62.0865.5579.3377.4759.0440.8931.26
Net profit46.6748.7859.1557.9743.6330.1723.05
Net profit margin+28.1%+32.4%+34.8%+39.1%+38.0%+33.3%+27.1%
EPS (β‚Ή)4.284.488.1439.9030.0320.7716.30
Balance sheet
Total assets45128020515010575.2950.84
Net worth28824820114910369.9442.19
Total debt16230.472.770.421.174.838.15
Cash & bank6.0912.558.169.3312.3527.642.08
Net working capital42.7432.2632.9546.8761.9851.3216.75
Cash flow
Cash from operations48.7891.0364.2139.4840.3110.530.63
Cash from investing(172)(112)(55.21)(20.41)(29.83)(2.25)(2.98)
Cash from financing11526.01(8.59)(13.27)(14.00)(5.16)2.10
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue47.4643.7944.2343.3742.3535.8737.7439.52
Revenue growth (YoY)+12.1%+22.1%+17.2%+9.7%+22.0%-7.6%--
Other income3.680.130.920.420.820.271.350.24
Total expenses29.7323.0024.8722.0621.4121.9521.7020.65
EBITDA17.7320.7919.3621.3120.9413.9216.0418.87
EBITDA margin+37.4%+47.5%+43.8%+49.1%+49.4%+38.8%+42.5%+47.7%
Depreciation3.993.974.043.892.962.031.231.56
Interest6.361.791.910.960.040.040.070.14
Profit before tax11.0615.1614.3316.8818.7612.1216.0917.41
Tax2.594.103.454.414.493.064.094.43

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 17 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue47.4643.7944.2343.3742.3535.8737.7439.52
Revenue growth (YoY)+12.1%+22.1%+17.2%+9.7%+22.0%-7.6%--
Other income3.680.130.920.420.820.271.350.24
Total expenses29.7323.0024.8722.0621.4121.9521.7020.65
EBITDA17.7320.7919.3621.3120.9413.9216.0418.87
EBITDA margin+37.4%+47.5%+43.8%+49.1%+49.4%+38.8%+42.5%+47.7%
Depreciation3.993.974.043.892.962.031.231.56
Interest6.361.791.910.960.040.040.070.14
Profit before tax11.0615.1614.3316.8818.7612.1216.0917.41
Tax2.594.103.454.414.493.064.094.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue16615117014811590.5685.12
Revenue growth+10.0%-11.2%+14.4%+29.2%+26.8%+6.4%-
Other income2.432.444.386.594.053.271.70
Total expenses89.4181.9691.1074.7556.8050.2353.28
Employee cost14.9911.4410.217.757.087.116.43
EBITDA76.4168.8478.7273.6458.0540.3331.84
EBITDA margin+46.1%+45.7%+46.4%+49.6%+50.5%+44.5%+37.4%
Depreciation12.925.373.542.582.231.731.36
Interest3.840.360.230.180.830.980.92
Profit before tax62.0865.5579.3377.4759.0440.8931.26
Tax15.4116.7720.1819.5015.4110.717.59
Net profit46.6748.7859.1557.9743.6330.1723.05
Net profit margin+28.1%+32.4%+34.8%+39.1%+38.0%+33.3%+27.1%
EPS (β‚Ή)4.284.488.1439.9030.0320.7716.30
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.9010.907.267.267.267.267.26
Reserves & surplus27723719414296.0662.6834.93
Shareholders' funds (net worth)28824820114910369.9442.19
Secured loans16029.890.000.000.000.000.00
Unsecured loans1.950.582.770.421.174.838.15
Total debt16230.472.770.421.174.838.15
Total liabilities45128020515010575.2950.84
Assets
Gross block31759.3351.2144.0428.2425.5221.93
Net block28941.2938.0232.6619.4318.9517.08
Capital work in progress12118491.2220.5912.702.070.36
Investments0.000.000.000.000.000.000.01
Inventories15.425.053.3314.6211.616.056.03
Sundry debtors60.9231.2427.0317.9125.1214.7120.23
Cash & bank balances6.0912.558.169.3312.3527.642.08
Loans & advances6.363.149.0519.8729.3114.920.79
Total current assets88.7951.9847.5761.7378.3963.3229.13
Total current liabilities46.0519.7214.6214.8616.4112.0012.38
Net working capital42.7432.2632.9546.8761.9851.3216.75
Total assets45128020515010575.2950.84
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash11.696.476.060.263.970.861.12
Net cash from operating activities48.7891.0364.2139.4840.3110.530.63
Net cash from investing activities(172)(112)(55.21)(20.41)(29.83)(2.25)(2.98)
Net cash from financing activities11526.01(8.59)(13.27)(14.00)(5.16)2.10
Net change in cash(8.57)5.220.415.79(3.51)3.12(0.26)
Closing cash6.0912.558.169.3312.3527.642.08
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+10.0%-11.2%+14.4%+29.2%+26.8%+6.4%-
EBITDA growth+11.0%-12.6%+6.9%+26.9%+43.9%+26.7%-
PBT growth-5.3%-17.4%+2.4%+31.2%+44.4%+30.8%+282.2%
Net income growth-4.3%-17.5%+2.0%+32.9%+44.6%+30.9%-
Revenue CAGR (3Y)+3.8%+9.5%+23.3%+20.4%+40.9%+32.7%+33.6%
EBITDA CAGR (3Y)+1.2%+5.9%+25.0%+32.3%+99.2%+86.3%+74.0%
Profitability & leverage
Net income margin+28.1%+32.4%+34.8%+39.1%+38.0%+33.3%+27.8%
Return on capital employed+18.1%+27.2%+44.8%+60.9%+66.4%+66.4%+84.8%
Return on net worth+17.4%+21.7%+33.8%+45.9%+50.4%+53.8%+78.0%
Debt / equity0.360.070.010.010.030.120.23
Long-term debt / equity0.300.070.000.000.010.040.05
Interest cover6.050.570.310.251.492.543.02
Efficiency & per share
Fixed asset turnover0.882.733.574.114.273.824.25
Inventory turnover16.2035.9918.9211.3113.0114.9926.73
Debtors turnover3.605.187.566.905.775.186.54
EPS (β‚Ή)4.284.488.1439.9030.0320.7716.30
Dividend per share (β‚Ή)0.670.671.005.4011.000.001.65
Book value per share (β‚Ή)26.4122.7927.72102.6671.1148.1429.04

Investments & Acquisitions by Gujarat Themis Biosyn

Gujarat Themis Biosyn has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include MicroBiopharm Japan.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Contract research and discovery services are provided to biopharma firms.
microbiopharm.comTokyo, Japan2011May 2026β€’β€’β€’β€’
Premium access

Complete acquisition details for Gujarat Themis Biosyn

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Gujarat Themis Biosyn

3 dated milestones of Gujarat Themis Biosyn across 45 years, from founding to its latest funding, stage changes and deals.

  1. Founded Gujarat Themis Biosyn is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Acquisition Acquires MicroBiopharm Japan.

Similar companies to Gujarat Themis Biosyn

Gujarat Themis Biosyn has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and Jubilant Pharma.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
lauruslabs.com2005Hyderabad, India$229.73M6,035
Pharmaceutical and biotechnology company
symbiotec.in2002Indore, India$61.01M1,822
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
jubilantpharma.com1978Noida, India
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company.
Premium access

Detailed similar companies of Gujarat Themis Biosyn

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Gujarat Themis Biosyn

The website of Gujarat Themis Biosyn (gtbl.in) receives about 3.6K visits a month.

  • Monthly visits
    3.6K

    ▲ 65.3% vs previous month

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Gujarat Themis Biosyn (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Gujarat Themis Biosyn

Gujarat Themis Biosyn: Aims to Integrate with MBJ for Increased Global Market Access and to Expand Product Line for Sustainable Growth.
Exchange Update β€’ 1 day ago
GUJTHEM: Q2 REVENUE 474.5M RUPEES VS 423M (YOY)
Exchange Update β€’ 3 days ago
GUJTHEM: Q2 SL NET PROFIT 85M RUPEES VS 143M (YOY)
Exchange Update β€’ 3 days ago
GUJTHEM: Q2 EBITDA 177M RUPEES VS 209M (YOY); Q2 EBITDA MARGIN 37.33% VS 49.46% (YOY)
Exchange Update β€’ 3 days ago
Gujarat Themis Biosyn: Company Finalizes Purchase Of Japan-Based Microbiopharm Japan Co., Ltd. To Enhance Fermentation Skills, Product Range, And Global Presence.
Exchange Update β€’ 2 months ago
Premium access

Complete news archive for Gujarat Themis Biosyn

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Gujarat Themis Biosyn

Gujarat Themis Biosyn was founded in 1981.

Gujarat Themis Biosyn is headquartered in Vapi, India. It is registered at Vapi, Gujarat, India.

Tapas Bhudebendranath Guhathakurata is the CEO of Gujarat Themis Biosyn, as recorded in our data.

Gujarat Themis Biosyn has 224 employees.

The primary company behind Gujarat Themis Biosyn, Gujarat Themis Biosyn Ltd, reported revenue of β‚Ή168 Cr for FY 2026, up 10% year on year.

Gujarat Themis Biosyn was established in 1981 and is headquartered in Vapi, India. Operations are centered on the information technology sector, where application development services are delivered to support software needs. The company functions within the software services industry, focusing on custom application solutions. Leadership is provided by CEO Tapas Bhudebendranath Guhathakurata, with activities conducted primarily in the Indian market.

Gujarat Themis Biosyn's top competitors include Laurus Labs, Symbiotec and Jubilant Pharma.

Gujarat Themis Biosyn offers Rifampicin.

Yes, Gujarat Themis Biosyn is publicly traded on NSE under the ticker symbol GUJTHEM.

Gujarat Themis Biosyn has made 1 acquisition, including MicroBiopharm Japan.

Gujarat Themis Biosyn operates through Gujarat Themis Biosyn Ltd.

The legal entities of Gujarat Themis Biosyn currently have 9 directors, including Dinesh Shantilal Patel, Sachin Dinesh Patel, Kirandeep Kaur Madan and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available